Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.53285
Abstract: Importance High-grade gliomas (HGGs) constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for grade 3 gliomas and 6.6% for grade 4 gliomas. The add-on efficacy of interferon alfa… read more here.
Keywords: grade gliomas; patients newly; newly diagnosed; alfa ... See more keywords